BIO: Moderna, Merck execs see possible speed bumps in COVID-19 vaccine manufacturing Regeneron starts testing COVID-19 antibody cocktail in humans Strategic National Stockpile aims to get 400M syringes by December for COVID-19 vaccine: officials BIO: What's the ROI on a COVID-19 vaccine? We have no idea, says Pfizer Here are the specialties hit hardest by the COVID-19 pandemic Centene, National Minority Quality Forum team up to study COVID-19's impact in minority communities Biopharma roundup: Eli Lilly, Regeneron push antibodies ahead; BioNTech and Moderna advance vaccine plans Healthcare roundup: House Dems open to liability protection; $8M awarded for training to support COVID-19 response Pfizer partner BioNTech scores €100M debt financing to fund COVID-19 vaccine production in Europe With COVID-19 test tubes in shortage, Coca-Cola bottlers offer a solution COVID-19 vaccine from China’s Sinopharm clears animal tests Featured Story | Thursday, June 11, 2020 With more than 130 vaccines against COVID-19 under development, headlines highlighting their progress swirl at a dizzying pace. But behind the scenes, execs at some of the leading players are intensely focused on the details needed to produce the candidates on a massive scale. read more |
| |
|---|
|
Top Stories Thursday, June 11, 2020 Regeneron has begun clinical development of its anti-SARS-CoV-2 antibody combination REGN-COV2. The adaptive phase 1/2/3 clinical trials will assess the effects of the antibodies on hospitalized and nonhospitalized COVID-19 patients. read more Tuesday, June 9, 2020 The Trump administration is working to get 400 million needles and syringes needed to distribute a COVID-19 vaccine that officials hope is ready by the end of the year. read more Thursday, June 11, 2020 Pfizer and its partner BioNTech are rushing to develop an mRNA vaccine against COVID-19 and ramp up production to meet demand. How much will that cost? And how will Pfizer price the vaccine? The company has to balance the demand from investors to answer those questions with the need for an effective vaccine, chief business officer John Young says. read more Thursday, June 11, 2020 The COVID-19 pandemic has hit the entire healthcare industry hard, but a new study shows which specialties are faring the worst. read more Wednesday, June 10, 2020 Centene Corporation and the National Minority Quality Forum are joining forces to study how the coronavirus pandemic is impacting communities of color. read more Thursday, June 11, 2020 Regeneron vaulted its antibody therapy into phase 1, while Eli Lilly said its own antibody treatment could be ready by September. BioNTech snared more than $100 million in vaccine funding from the EIB, while Moderna confirmed a large phase 3 for its shot. And case counts soared in Arizona post-reopening, prompting a congressman's call-to-action. read more Thursday, June 11, 2020 Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more Thursday, June 11, 2020 BioNTech and Pfizer are among the front-runners in the closely watched COVID-19 vaccine race, and as they simultaneously work through development and scale up manufacturing, BioNTech has scored a €100 million financing agreement to help fund production in Europe. read more Thursday, June 11, 2020 A group of independent soda bottle manufacturers working for Coca-Cola has pivoted to help produce the test tubes needed for COVID-19 diagnostic kits. read more Thursday, June 11, 2020 An inactivated COVID-19 vaccine by China's state-owned Sinopharm has induced high levels of neutralizing antibodies against the novel coronavirus in animal tests. The vaccine is made from an inactivated form of the virus—a conventional technology— but it could have some advantages over next-generation platforms. read more |
